Literature DB >> 956812

Present morality in parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths.

S G Diamond, C H Markham.   

Abstract

Excess mortality, i.e. more deaths than expected in a similar normal population, has been reduced in Parkinson's disease by levodopa. A California series and a large collaborative study throughout the United States show the ratio of observed to expected deaths to be normal. In contrast, a New York study was similar patients and a Montreal group of much more severely disabled patients showed greater mortality. The reasons for these differences are unclear, but some variations in results may be attributed to different methods of calculating expected deaths to derive the ratio of observed to expected deaths.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 956812     DOI: 10.1007/BF01249443

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  6 in total

1.  Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.

Authors:  R D Sweet; F H McDowell
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

Review 2.  Parkinson's disease and levodopa. A five-year follow-up and review.

Authors:  C H Markham; L J Treciokas; S G Diamond
Journal:  West J Med       Date:  1974-09

3.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Six years of high-level levodopa therapy in severely akinetic parkinsonian patients.

Authors:  A Barbeau
Journal:  Arch Neurol       Date:  1976-05

6.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.

Authors:  M D Yahr; R C Duvoisin; M M Hoehn; M J Schear; R E Barrett
Journal:  Trans Am Neurol Assoc       Date:  1968
  6 in total
  9 in total

1.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

2.  Seniors with Parkinson's disease: initial medical treatment.

Authors:  J Eric Ahlskog
Journal:  J Clin Neurol       Date:  2010-12-31       Impact factor: 3.077

3.  Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients.

Authors:  T S Elizan; H Sroka; H Maker; H Smith; M D Yahr
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

Review 4.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

5.  Mortality of patients with Parkinson's disease treated with levodopa.

Authors:  R J Marttila; U K Rinne; T Siirtola; V Sonninen
Journal:  J Neurol       Date:  1977-10-07       Impact factor: 4.849

6.  Epidemiology of Parkinson's disease--an overview.

Authors:  R J Marttila; U K Rinne
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Treatment of Parkinson's disease: problems with a progressing disease.

Authors:  U K Rinne
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

8.  Mortality in levodopa-treated Parkinson's disease.

Authors:  John C Morgan; Lillian J Currie; Madaline B Harrison; James P Bennett; Joel M Trugman; G Frederick Wooten
Journal:  Parkinsons Dis       Date:  2014-01-28

9.  Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

Authors:  Y Ben-Shlomo; M G Marmot
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.